Dobutamine: development of a new catecholamine to selectively increase cardiac contractility
about
Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogsDopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptorsCharacterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testingMapping of intracellular pH in the in vivo rodent heart using hyperpolarized [1-13C]pyruvate.Adaptation of myocardial blood flow to increased metabolic demand is not dependent on endothelial vasodilators in the rat heart.Three-dimensional pharmacology, a subject ranging from ignorance to overstatements.Minimally invasive, patient specific, beat-by-beat estimation of left ventricular time varying elastanceCatecholamine stress echocardiography.Assessing cardiac pumping capability by exercise testing and inotropic stimulation.β-Adrenergic receptor-PI3K signaling crosstalk in mouse heart: elucidation of immediate downstream signaling cascades.Beta-adrenoceptor blocking drugs: the relevance of intrinsic sympathomimetic activityDopamine and dobutamine in pediatric therapy.The use of dobutamine in myocardial infarction for reversal of the cardiodepressive effect of metoprololDevelopment of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Anthrax edema toxin has cAMP-mediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart model.Comparison of haemodynamic responses to dobutamine and salbutamol in cardiogenic shock after acute myocardial infarction.The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.Catecholamines in critical care. The commonly used catecholamines: receptor and clinical profile, indications and dosages.Bretylium and dobutamine in the treatment of coronary artery disease.Factors Associated with Mortality and Graft Failure in Liver Transplants: A Hierarchical ApproachRegulation of oxidative phosphorylation complex activity: effects of tissue-specific metabolic stress within an allometric series and acute changes in workload.Influence of heart rate on the effects of prenalterol on regional myocardial blood flow and function during coronary stenosis in dogsFunctional antagonism as a means of determining dissociation constants and relative efficacies of sympathomimetic amines in guinea-pig isolated atriaThe cardiovascular pharmacology of 7-propyl-theo-phylline-dopamine (D4975); comparison with dopamine and dobutamine.Dissociation constants of isoprenaline and orciprenaline and their relative efficacies on guinea-pig isolated atria determined by use of an irreversible beta-adrenoceptor antagonistFeasibility, safety and tolerability of accelerated dobutamine stress echocardiography.Solid phase extraction and high performance liquid chromatographic determination of dobutamine in plasma of dialysed patients.Haemodynamic effects of dobutamine with special reference to myocardial blood flow. A comparison with dopamine and isoprenaline.Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.Antitumor activity of dobutamine on human osteosarcoma cells.In vivo and in vitro cardiac responses to beta-adrenergic stimulation in volume-overload heart failureSelectivity of dobutamine for adrenergic receptor subtypes: in vitro analysis by radioligand binding.Can we do better than dobutamine?The appropriate use of inotropes in shock.Dobutamine: ten years later.From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery.Assessment of two in vitro methods for determination of the apparent affinities of beta-sympathomimetics on myocardial contractility.Differentiation of cardiac chronotropic and inotropic effects of beta-adrenoceptor agonists.Hemodynamic effects of prenalterol, a beta1-adrenoreceptor agonist, in hypotension induced by high thoracic epidural block in man.Cardiovascular effects of prenalterol (H133/22) in normal man
P2860
Q24673440-2847BD8C-B731-4FD7-92F4-94CA8454DE8BQ24674107-8F343802-68DD-4256-A858-1B2189751BFAQ28285407-0EEC93DD-DF34-4AE6-8110-D7677752D5CEQ30489329-0DDB75F8-98D6-43BC-9226-3344B6D44F9FQ30535389-0FF5C154-801E-4341-91BA-16B6717C41ECQ31027709-2BE7C340-1685-4FA9-9243-6FEB7255B6A8Q33560635-FE3E824B-176C-4F32-9F61-6B7E3F7DAE55Q33565122-31B67627-F176-4874-AB80-D140C8243FB0Q34000206-81D9EBF0-20D9-4B8B-A076-E430CE7A3EDBQ34058699-0DD51C8D-1198-494A-AFFE-C423447BBB11Q34450370-56038052-DEB6-4578-B8D2-E11F7295FDD4Q34511409-139E76B5-127A-46BC-A9CD-3F5363C0D6C7Q34516618-CB89F025-7A92-41C9-B5F5-437B4FE5A315Q34538482-ABFA4B1C-19B5-42B4-9EDC-D92A98E6AB92Q34720370-C1C1BF0C-C4F6-402B-83A9-030621037A0BQ34746930-768EA070-932F-43F2-8838-AF63755C76DDQ34776831-D9C0AECF-1A3B-4AEB-93CF-C52B72322601Q35530734-82259EF8-C3C9-4290-BC72-2447C56A4E02Q35657396-D3CC9930-6418-4761-AF98-0A75FB801827Q35956015-E1A94972-726A-4945-B4AF-F697BFBA2CA8Q35994285-9A929722-EC62-4448-83B1-8DF4B3FF4089Q36004262-38AA7868-7B8A-4300-A021-993BE56476B2Q36096012-7AFA7144-FF40-41FC-8653-E16A6BA6D395Q36096206-099F3DF7-61DD-467C-BAF6-D348B7370962Q36128163-5865C9A0-27E0-46F4-A5D4-772B37BD5DE6Q36389320-17391143-01D5-441A-A18B-65F0B2EDC6B4Q36719471-1FA15D7A-70D4-4270-896F-F1C22E00FB44Q36766140-D5B009DF-43D0-4256-B298-643002430E67Q36848480-96322D4F-CFCF-4339-8C9F-B899B595BD7EQ36953612-EA5CE46B-24D2-4F84-8239-B6EE3FB292D2Q36968582-0290C672-6E8E-42E3-8C12-11C5EF137716Q37000137-B1EF948C-B606-43DD-ACB5-58C34B7F94BCQ37406997-FB3E6B79-0E82-49E8-A68D-4E0022FCCDE6Q37936637-9582A22D-CAD5-406D-98CA-E72324CC29A4Q38683788-3A4454DF-6E5F-46CF-9D53-50EEA40868F4Q39030459-22B272A0-468C-4D34-AC92-C50CAC4BA9F6Q39118154-10326B83-2517-4C86-B86B-C4B00E69A8BEQ39176773-518E07F8-A28D-40B6-87AF-A8E6774389AAQ39241565-C84D29AD-B7D6-4BFF-8935-718063A12BE4Q39251304-FE84AC5A-6E27-436C-9576-54D71548EFDD
P2860
Dobutamine: development of a new catecholamine to selectively increase cardiac contractility
description
1975 nî lūn-bûn
@nan
1975 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1975 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
name
Dobutamine: development of a n ...... increase cardiac contractility
@ast
Dobutamine: development of a n ...... increase cardiac contractility
@en
Dobutamine: development of a n ...... increase cardiac contractility
@nl
type
label
Dobutamine: development of a n ...... increase cardiac contractility
@ast
Dobutamine: development of a n ...... increase cardiac contractility
@en
Dobutamine: development of a n ...... increase cardiac contractility
@nl
prefLabel
Dobutamine: development of a n ...... increase cardiac contractility
@ast
Dobutamine: development of a n ...... increase cardiac contractility
@en
Dobutamine: development of a n ...... increase cardiac contractility
@nl
P3181
P356
P1433
P1476
Dobutamine: development of a n ...... increase cardiac contractility
@en
P2093
P304
P3181
P356
10.1161/01.RES.36.1.185
P407
P577
1975-01-01T00:00:00Z